265 related articles for article (PubMed ID: 19147564)
1. Identification of nuclear export inhibitors with potent anticancer activity in vivo.
Mutka SC; Yang WQ; Dong SD; Ward SL; Craig DA; Timmermans PB; Murli S
Cancer Res; 2009 Jan; 69(2):510-7. PubMed ID: 19147564
[TBL] [Abstract][Full Text] [Related]
2. Nuclear entrapment of p33ING1b by inhibition of exportin-1: A trigger of apoptosis in head and neck squamous cell cancer.
Özdaş S
Cell Mol Biol (Noisy-le-grand); 2018 Apr; 64(5):66-72. PubMed ID: 29729696
[TBL] [Abstract][Full Text] [Related]
3. Ratjadone and leptomycin B block CRM1-dependent nuclear export by identical mechanisms.
Meissner T; Krause E; Vinkemeier U
FEBS Lett; 2004 Oct; 576(1-2):27-30. PubMed ID: 15474004
[TBL] [Abstract][Full Text] [Related]
4. Leptomycin B alters the subcellular distribution of CRM1 (Exportin 1).
Rahmani K; Dean DA
Biochem Biophys Res Commun; 2017 Jun; 488(2):253-258. PubMed ID: 28412356
[TBL] [Abstract][Full Text] [Related]
5. A method for quantification of exportin-1 (XPO1) occupancy by Selective Inhibitor of Nuclear Export (SINE) compounds.
Crochiere ML; Baloglu E; Klebanov B; Donovan S; Del Alamo D; Lee M; Kauffman M; Shacham S; Landesman Y
Oncotarget; 2016 Jan; 7(2):1863-77. PubMed ID: 26654943
[TBL] [Abstract][Full Text] [Related]
6. Novel reversible selective inhibitor of nuclear export shows that CRM1 is a target in colorectal cancer cells.
Niu M; Chong Y; Han Y; Liu X
Cancer Biol Ther; 2015; 16(7):1110-8. PubMed ID: 25996664
[TBL] [Abstract][Full Text] [Related]
7. CBS9106 is a novel reversible oral CRM1 inhibitor with CRM1 degrading activity.
Sakakibara K; Saito N; Sato T; Suzuki A; Hasegawa Y; Friedman JM; Kufe DW; Vonhoff DD; Iwami T; Kawabe T
Blood; 2011 Oct; 118(14):3922-31. PubMed ID: 21841164
[TBL] [Abstract][Full Text] [Related]
8. Selinexor, a Selective Inhibitor of Nuclear Export (SINE) compound, acts through NF-κB deactivation and combines with proteasome inhibitors to synergistically induce tumor cell death.
Kashyap T; Argueta C; Aboukameel A; Unger TJ; Klebanov B; Mohammad RM; Muqbil I; Azmi AS; Drolen C; Senapedis W; Lee M; Kauffman M; Shacham S; Landesman Y
Oncotarget; 2016 Nov; 7(48):78883-78895. PubMed ID: 27713151
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of CRM1 activity sensitizes endometrial and ovarian cell lines to TRAIL-induced cell death.
Fabi F; Adam P; Vincent K; Demontigny F; Parent S; Joncas FH; Asselin E
Cell Commun Signal; 2018 Jul; 16(1):39. PubMed ID: 29973205
[TBL] [Abstract][Full Text] [Related]
10. Preclinical activity of a novel CRM1 inhibitor in acute myeloid leukemia.
Ranganathan P; Yu X; Na C; Santhanam R; Shacham S; Kauffman M; Walker A; Klisovic R; Blum W; Caligiuri M; Croce CM; Marcucci G; Garzon R
Blood; 2012 Aug; 120(9):1765-73. PubMed ID: 22677130
[TBL] [Abstract][Full Text] [Related]
11. Leptomycin B inhibition of signal-mediated nuclear export by direct binding to CRM1.
Kudo N; Wolff B; Sekimoto T; Schreiner EP; Yoneda Y; Yanagida M; Horinouchi S; Yoshida M
Exp Cell Res; 1998 Aug; 242(2):540-7. PubMed ID: 9683540
[TBL] [Abstract][Full Text] [Related]
12. Nucleocytoplasmic shuttling and the biological activity of mouse survivin are regulated by an active nuclear export signal.
Stauber RH; Rabenhorst U; Rekik A; Engels K; Bier C; Knauer SK
Traffic; 2006 Nov; 7(11):1461-72. PubMed ID: 16984408
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of CRM1-dependent nuclear export sensitizes malignant cells to cytotoxic and targeted agents.
Turner JG; Dawson J; Cubitt CL; Baz R; Sullivan DM
Semin Cancer Biol; 2014 Aug; 27():62-73. PubMed ID: 24631834
[TBL] [Abstract][Full Text] [Related]
14. Antileukemic activity of nuclear export inhibitors that spare normal hematopoietic cells.
Etchin J; Sun Q; Kentsis A; Farmer A; Zhang ZC; Sanda T; Mansour MR; Barcelo C; McCauley D; Kauffman M; Shacham S; Christie AL; Kung AL; Rodig SJ; Chook YM; Look AT
Leukemia; 2013 Jan; 27(1):66-74. PubMed ID: 22847027
[TBL] [Abstract][Full Text] [Related]
15. CRM1 protein-mediated regulation of nuclear clusterin (nCLU), an ionizing radiation-stimulated, Bax-dependent pro-death factor.
Leskov KS; Araki S; Lavik JP; Gomez JA; Gama V; Gonos ES; Trougakos IP; Matsuyama S; Boothman DA
J Biol Chem; 2011 Nov; 286(46):40083-90. PubMed ID: 21953454
[TBL] [Abstract][Full Text] [Related]
16. Nuclear export of proteins and drug resistance in cancer.
Turner JG; Dawson J; Sullivan DM
Biochem Pharmacol; 2012 Apr; 83(8):1021-32. PubMed ID: 22209898
[TBL] [Abstract][Full Text] [Related]
17. KPT-330 inhibitor of XPO1-mediated nuclear export has anti-proliferative activity in hepatocellular carcinoma.
Zheng Y; Gery S; Sun H; Shacham S; Kauffman M; Koeffler HP
Cancer Chemother Pharmacol; 2014 Sep; 74(3):487-95. PubMed ID: 25030088
[TBL] [Abstract][Full Text] [Related]
18. TRAIL responses are enhanced by nuclear export inhibition in osteosarcoma.
Phillips KL; Wright N; McDermott E; Cross NA
Biochem Biophys Res Commun; 2019 Sep; 517(2):383-389. PubMed ID: 31362889
[TBL] [Abstract][Full Text] [Related]
19. Novel small molecule XPO1/CRM1 inhibitors induce nuclear accumulation of TP53, phosphorylated MAPK and apoptosis in human melanoma cells.
Yang J; Bill MA; Young GS; La Perle K; Landesman Y; Shacham S; Kauffman M; Senapedis W; Kashyap T; Saint-Martin JR; Kendra K; Lesinski GB
PLoS One; 2014; 9(7):e102983. PubMed ID: 25057921
[TBL] [Abstract][Full Text] [Related]
20. KPT-330 inhibitor of CRM1 (XPO1)-mediated nuclear export has selective anti-leukaemic activity in preclinical models of T-cell acute lymphoblastic leukaemia and acute myeloid leukaemia.
Etchin J; Sanda T; Mansour MR; Kentsis A; Montero J; Le BT; Christie AL; McCauley D; Rodig SJ; Kauffman M; Shacham S; Stone R; Letai A; Kung AL; Thomas Look A
Br J Haematol; 2013 Apr; 161(1):117-27. PubMed ID: 23373539
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
